The JPMorgan Chase & Co. Sold 141,635 Shares of Steris Corp. (STE)

The JPMorgan Chase & Co. Sold 141,635 Shares of Steris Corp. (STE)

JPMorgan Chase & Co. decreased its stake in Steris Corp. (NYSE:STE) by 29.3% during the third quarter, according to its most recent filing with the SEC. The fund owned 342,159 shares of the company’s stock after selling 141,635 shares during the period. JPMorgan Chase & Co.’s holdings in Steris Corp. were worth $25,013,000 as of its most recent filing with the SEC.

A number of other large investors have also modified their holdings of the company. Janus Capital Management LLC boosted its stake in shares of Steris Corp. by 28.7% in the second quarter. Janus Capital Management LLC now owns 5,022,412 shares of the company’s stock worth $345,288,000 after buying an additional 1,120,438 shares during the last quarter. Wells Fargo & Company MN boosted its stake in shares of Steris Corp. by 10.3% in the third quarter. Wells Fargo & Company MN now owns 3,271,198 shares of the company’s stock worth $239,125,000 after buying an additional 306,064 shares during the last quarter. Westfield Capital Management Co. LP boosted its stake in shares of Steris Corp. by 2.2% in the second quarter. Westfield Capital Management Co. LP now owns 3,035,201 shares of the company’s stock worth $208,670,000 after buying an additional 64,702 shares during the last quarter. Massachusetts Financial Services Co. MA boosted its stake in shares of Steris Corp. by 7.0% in the second quarter. Massachusetts Financial Services Co. MA now owns 1,963,285 shares of the company’s stock worth $134,975,000 after buying an additional 128,956 shares during the last quarter. Finally, Fisher Asset Management LLC boosted its stake in shares of Steris Corp. by 1.0% in the third quarter. Fisher Asset Management LLC now owns 1,639,312 shares of the company’s stock worth $119,834,000 after buying an additional 16,808 shares during the last quarter. 91.45% of the stock is currently owned by hedge funds and other institutional investors.

Steris Corp. (NYSE:STE) traded up 0.23% on Friday, reaching $69.21. 78,810 shares of the company’s stock traded hands. The stock has a market cap of $5.90 billion, a price-to-earnings ratio of 34.94 and a beta of 1.27. Steris Corp. has a 52-week low of $61.38 and a 52-week high of $78.77. The company’s 50 day moving average is $66.86 and its 200-day moving average is $69.13.

Steris Corp. (NYSE:STE) last posted its quarterly earnings results on Wednesday, November 2nd. The company reported $0.89 EPS for the quarter, missing analysts’ consensus estimates of $0.90 by $0.01. The company earned $646.40 million during the quarter, compared to analyst estimates of $670.24 million. Steris Corp. had a return on equity of 9.89% and a net margin of 6.41%. The company’s revenue for the quarter was up 31.9% compared to the same quarter last year. During the same quarter in the previous year, the business posted $0.83 earnings per share. Equities analysts expect that Steris Corp. will post $3.89 EPS for the current year.

The firm also recently disclosed a quarterly dividend, which was paid on Wednesday, December 21st. Stockholders of record on Wednesday, November 23rd were issued a dividend of $0.28 per share. This represents a $1.12 dividend on an annualized basis and a dividend yield of 1.62%. The ex-dividend date of this dividend was Monday, November 21st. Steris Corp.’s dividend payout ratio is currently 57.14%.

A number of equities research analysts have recently issued reports on the stock. Goldman Sachs Group Inc. assumed coverage on shares of Steris Corp. in a report on Wednesday, November 30th. They issued a “neutral” rating and a $71.00 target price on the stock. Zacks Investment Research raised shares of Steris Corp. from a “sell” rating to a “hold” rating in a report on Wednesday, December 7th. Finally, JMP Securities reaffirmed a “buy” rating on shares of Steris Corp. in a report on Friday, November 4th.

In related news, VP John Adam Zangerle sold 2,200 shares of the business’s stock in a transaction dated Tuesday, November 15th. The shares were sold at an average price of $67.00, for a total transaction of $147,400.00. Following the transaction, the vice president now directly owns 26,166 shares in the company, valued at $1,753,122. The transaction was disclosed in a filing with the SEC, which can be accessed through the SEC website. Also, Director Cynthia L. Feldmann sold 4,744 shares of the business’s stock in a transaction dated Friday, November 4th. The stock was sold at an average price of $64.98, for a total transaction of $308,265.12. Following the transaction, the director now owns 14,581 shares in the company, valued at $947,473.38. The disclosure for this sale can be found here. Insiders own 2.52% of the company’s stock.

Steris Corp. Company Profile

STERIS Corporation (STERIS) is a provider of infection prevention and other procedural products and services. The Company is focused on healthcare, pharmaceutical and research. The Company operates through three business segments: Healthcare, Life Sciences and STERIS Isomedix Services. The Healthcare segment provides surgical, sterile processing, infection prevention and gastrointestinal solutions.

Related posts

Leave a Comment